The cosmetic industry is constantly evolving to create new formulations that offer controlled and specific release of active ingredients, as well as greater penetration, duration and stability of the resulting products. To fulfil all these objectives, the use of cyclodextrins in different cosmetic formulations is being considered. CDs are cyclic oligosaccharides with a hydrophilic outer surface and an inner cavity able to encapsulate hydrophobic molecules. This property can be used to form complexes with hydrophobic molecules and solubilise them in aqueous matrices, such as creams or gels. This review analyses the main advantages that these agents provide in cosmetic products, such as protection, administration and controlled release of bioactive ingredients, improved water solubility, reduced fragrance volatility, masking off unpleasant odours, modification of the physicochemical properties of formulations or prevention of ingredient side effects, among others. Formulations of lotions, sunscreens, deodorants, gels or perfumes containing CDs are already on the market, and new ones are being developed. Moreover, the regulations concerning their use, the types of cyclodextrins allowed and the mechanism required to produce CD-guest inclusion complexes are reviewed. Likewise, the use of CDs alone or encapsulating other compounds makes them an extremely versatile nanomaterial for dermofacial and cosmetic formulations.
Isorhapontigenin has been proposed as a better alternative for oral administration than the famous resveratrol, as it shares many biological activities, but with a structure that could make its delivery easier. Although this hydrophobic structure could enhance bioavailability, it could also be a disadvantage in the development of products. In this research, we study the antiproliferative activity of this stilbene against colorectal cancer and overcome its limitations through molecular encapsulation in cyclodextrins. The cytotoxic activity against human colorectal cancer cells of isorhapontigenin was similar to that of resveratrol or piceatannol, supporting its use as a bioactive alternative. The study of the encapsulation through fluorescence spectroscopy and molecular docking revealed that the complexation satisfies a 1:1 stoichiometry and that HP-β-CD is the most suitable CD to encapsulate this stilbene. Through a spectrophotometric assay, it was observed that this CD could double the basal water solubility, exceeding the solubility of other hydroxylated stilbenes. The stability of these inclusion complexes was higher at a pH below 9 and refrigeration temperatures. Moreover, the use of CDs retained more than 78% of isorhapontigenin after storage for 12 weeks, compared to 15% in free form. Overall, these findings could help design novel formulations to better deliver isorhapontigenin.
It has been argued that methoxylated stilbenes are better candidates for oral administration than hydroxylated stilbenes, including resveratrol, as they share many biological activities but have better bioavailability. By contrast, they have a disadvantage to consider, i.e., their lower hydrophilic character that leads to precipitation issues in the final product. In this work, we analysed and compared the growth inhibition of colorectal cancer cells of the methoxylated stilbene rhapontigenin and some analogues and overcame potential problems in the development of fortified products by designing inclusion complexes. Among several cyclodextrins, we found the one that best fit the molecule by physicochemical and bioinformatics assays. The stoichiometry and the encapsulation constants with natural and modified cyclodextrins were determined by fluorescence spectroscopy. The most promising complexes were analysed at different temperature and pH conditions, determining the thermodynamic parameters, to discover the optimal conditions for the preparation and storage of the products. The results showed that rhapontigenin solubility and stability were significantly improved, achieving a sevenfold increase in water solubility and maintaining more than 73% of the stilbene after three months. These findings could be of great interest for industries that aim to deliver novel bioactive compounds with higher solubility and lower degradation.
Cyclodextrin-based nanosponges (CD-NSs) have gained importance in drug delivery in the last years due to their easy synthesis and versatility. However, their use as carriers for the delivery of macromolecules such as proteins is less known and sometimes difficult to consider. In this entry, the authors summarize and highlight the multiple possibilities of CD-NSs to deliver active proteins, improving their activity or stability. Starting with a brief description of CD-NSs and their characteristics, the entry will be focused on several proteins, such as (1) Lipase, (2) Insulin and (3) Nisin, for chemical or pharmaceutical applications. The revised results demonstrated that CD-NSs can generate different and interesting applications with proteins. These results could be added to their uses with small drugs, being an interesting alternative for protein delivery and applicability.
Background/Objectives: Pinostilbene is a naturally occurring methoxylated stilbene with many beneficial health properties, including antioxidant, antimicrobial and neuroprotective activities. This stilbene has also been shown to possess anticancer or cytotoxic activity in some cancers. As in the case of other stilbenes, pinostilbene is very labile, degrades rapidly under stress conditions and is poorly water-soluble, which poses a drawback to its use as a drug. This work aims to provide further insights into its cytotoxicity activity in a colon cancer cell line and to overcome its physicochemical limitations by encapsulating the molecule in cyclodextrins. Methods: The anticancer activity was evaluated in vitro in Caco-2 colorectal cells using the neutral red assay. Subsequently, a screening of cyclodextrins was carried out to determine the one with the highest encapsulation constant, as well as the encapsulation stoichiometry, using fluorescence spectroscopy and molecular docking predictions. The formation of the inclusion complexes was checked by differential scanning calorimetry and scanning electron microscopy. The protective effect of cyclodextrins on pinostilbene release was monitored through spectrophotometric measurements over time. Results: Pinostilbene showed in vitro cytotoxicity activity in Caco-2 colorectal cells by the neutral red assay. This study revealed that the cyclodextrin with the highest encapsulation constant was the hydroxypropyl-β-cyclodextrin (KF = 10,074.45 ± 503.72 M−1), and the encapsulation stoichiometry was 1:1. DSC and SEM assays confirmed the formation of these inclusion complexes. Cyclodextrins were able to satisfactorily reduce pinostilbene degradation from 31% to less than 15% after 3 months, as well as increase its water solubility up to 10 times and enhance its release as a function of the pH of the medium. Conclusions: Pinostilbene is a promising drug candidate with strong in vitro antiproliferative activity. Many of its physicochemical limitations can be overcome with cyclodextrins, which opens the door to its future use in the pharmaceutical and food industries.
Phosphodiesterase 4 (PDE4) is a key enzyme responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP), thereby regulating essential signaling pathways involved in inflammation and immune modulation. Structural studies have demonstrated a high degree of conservation within the catalytic domains of PDE4 isoforms, accompanied by subtle conformational variations that underlie their selectivity and tissue-specific distribution. Elucidating these structural features has been instrumental in guiding the rational design of PDE4 inhibitors. Although synthetic PDE4 inhibitors such as roflumilast and apremilast exhibit significant therapeutic efficacy, their clinical application is often limited by dose-dependent adverse effects. These effects primarily arise from insufficient isoform selectivity, as current inhibitors tend to target multiple PDE4 subtypes indiscriminately, resulting in off-target pharmacological actions and reduced tolerability. In contrast, natural products—including flavonoids, terpenoids, and related polyphenolic compounds such as curcumin, α-mangostin, and their derivatives—have emerged as promising molecular scaffolds. Their lower toxicity, favorable biocompatibility, and structural diversity enable fine-tuning of potency and selectivity through rational modification. Integrating structural insights derived from crystallographic and computational studies with the optimization of natural compounds offers a sustainable and effective strategy for the development of safer, isoform-selective PDE4-targeted therapies.